Zydus Lifesciences shares zoom 7% after USFDA nod for Dasatinib tablets

Zydus Lifesciences shares surged 7% to an intraday high of Rs 947.95 on the BSE on Thursday after receiving final approval from the United States Food and Drug Administration (USFDA) to market Dasatinib tablets in multiple strengths—20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

"Zydus has received final approval from the USFDA to manufacture Dasatinib tablets in various strengths (USRLD: Sprycel® Tablets)," the company said in an exchange filing.

The drug is a generic version of Sprycel tablets, which had annual US sales of $1807.7 million, according to IQVIA MAT data as of January 2025.


Also Read:Peter Schiff calls Trump’s crypto reserve push a ‘Pump and Dump’, demands congressional probe

Dasatinib is used to treat newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

It is also prescribed for adults with chronic, accelerated, or blast phase Ph+ CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in cases of resistance or intolerance to prior therapies. Zydus will manufacture the tablets at its Ahmedabad SEZ facility.

Also Read: Stocks in news: Wipro, IRFC, TCS, Zydus Life, LIC Housing

With this approval, Zydus has secured 415 regulatory clearances and has filed 483 (As of December 31, 2024) Abbreviated New Drug Applications (ANDAs) since FY 2003-04.

Zydus Lifesciences shares target price

As per Trendlyne data, the average target price of the stock is Rs 1,075, which shows an upside of 21% from the current market prices. The consensus recommendation from 31 analysts for the stock is a 'Hold'.

Also Read: Chip is the new oil! Jefferies expects India to quadruple electronics production to Rs 500 billion by 2030—Key stocks to watch

Zydus Lifesciences shares performance

On Wednesday, Zydus Lifesciences shares closed at Rs 887.5, up 1.8% on the BSE, while the benchmark Sensex surged 1%. The stock has declined 20% in the last six months but gained 88% in the last two years. The company’s market capitalization stands at Rs 89,308 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)